Research programme: coeliac disease therapies - Numerate/Stanford University

Drug Profile

Research programme: coeliac disease therapies - Numerate/Stanford University

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Numerate; Stanford University
  • Class Small molecules
  • Mechanism of Action Transglutaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Coeliac disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Coeliac disease in USA
  • 19 Mar 2009 Numerate receives Small Business Technology Transfer (STTR) Phase 1 grant from National Institutes of Health for research collaboration with Stanford University for development of transglutaminase 2 inhibitors in Coeliac disease
  • 19 Mar 2009 Early research in Coeliac disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top